Prothena | PRTA - Ebit

Stock Price
9.76
Daily Change
-0.10 -1.01%
Monthly
-7.22%
Yearly
35.93%
Q2 Forecast
10.41

Prothena reported $-27.21M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD -48.28M 37.33M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amgen USD 3.83B 130M Mar/2026
Biogen USD 514.3M 502.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Exelixis USD 251.34M 15.43M Mar/2026
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD 344.17M 39.71M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
MacroGenics USD -12.1M 32.26M Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Prothena USD -27.21M 12.55M Dec/2025
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026
Xoma USD -10.08M 4.4M Jun/2024